
    
      This is a phase 2 single dose, randomized, double-blind, placebo-controlled, multi center
      study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HemaMaxâ„¢
      (rHuIL-12) in healthy adult male and female subjects considered representative of U.S.
      population.
    
  